CRM vs. JNJ: A Head-to-Head Stock Comparison

Updated on August 23, 2025

Here’s a clear look at CRM and JNJ, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

Symbol	CRM	JNJ
Company Name	Salesforce, Inc.	Johnson & Johnson
Country	United States	United States
GICS Sector	Information Technology	Health Care
GICS Industry	Software	Pharmaceuticals
Market Capitalization	235.61 billion USD	430.71 billion USD
Exchange	NYSE	NYSE
Listing Date	June 23, 2004	January 2, 1962
Security Type	Common Stock	Common Stock

Historical Performance

This chart compares the performance of CRM and JNJ by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

CRM vs. JNJ: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

Symbol	CRM	JNJ
5-Day Price Return	5.60%	2.36%
13-Week Price Return	-14.32%	17.28%
26-Week Price Return	-25.28%	13.73%
52-Week Price Return	-7.13%	12.03%
Month-to-Date Return	-4.60%	8.56%
Year-to-Date Return	-26.29%	23.66%
10-Day Avg. Volume	9.91M	8.34M
3-Month Avg. Volume	7.34M	8.37M
3-Month Volatility	25.55%	17.92%
Beta	1.23	0.38

Profitability

Return on Equity (TTM)

CRM

10.43%

Software Industry

Max: 59.01%
Q3: 21.98%
Median: 7.15%
Q1: -11.12%
Min: -51.24%

CRM’s Return on Equity of 10.43% is on par with the norm for the Software industry, indicating its profitability relative to shareholder equity is typical for the sector.

JNJ

30.39%

Pharmaceuticals Industry

Max: 38.59%
Q3: 19.84%
Median: 11.90%
Q1: 5.63%
Min: -9.96%

In the upper quartile for the Pharmaceuticals industry, JNJ’s Return on Equity of 30.39% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.

CRM vs. JNJ: A comparison of their Return on Equity (TTM) against their respective Software and Pharmaceuticals industry benchmarks.

Net Profit Margin (TTM)

CRM

16.08%

Software Industry

Max: 48.14%
Q3: 18.23%
Median: 5.60%
Q1: -9.22%
Min: -49.36%

CRM’s Net Profit Margin of 16.08% is aligned with the median group of its peers in the Software industry. This indicates its ability to convert revenue into profit is typical for the sector.

JNJ

25.00%

Pharmaceuticals Industry

Max: 34.51%
Q3: 17.73%
Median: 12.12%
Q1: 5.99%
Min: -7.73%

A Net Profit Margin of 25.00% places JNJ in the upper quartile for the Pharmaceuticals industry, signifying strong profitability and more effective cost management than most of its peers.

CRM vs. JNJ: A comparison of their Net Profit Margin (TTM) against their respective Software and Pharmaceuticals industry benchmarks.

Operating Profit Margin (TTM)

CRM

18.10%

Software Industry

Max: 57.34%
Q3: 20.60%
Median: 7.84%
Q1: -8.72%
Min: -51.37%

CRM’s Operating Profit Margin of 18.10% is around the midpoint for the Software industry, indicating that its efficiency in managing core business operations is typical for the sector.

JNJ

30.18%

Pharmaceuticals Industry

Max: 41.53%
Q3: 23.00%
Median: 16.24%
Q1: 9.24%
Min: -6.94%

An Operating Profit Margin of 30.18% places JNJ in the upper quartile for the Pharmaceuticals industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.

CRM vs. JNJ: A comparison of their Operating Profit Margin (TTM) against their respective Software and Pharmaceuticals industry benchmarks.

Profitability at a Glance

Symbol	CRM	JNJ
Return on Equity (TTM)	10.43%	30.39%
Return on Assets (TTM)	6.44%	12.16%
Net Profit Margin (TTM)	16.08%	25.00%
Operating Profit Margin (TTM)	18.10%	30.18%
Gross Profit Margin (TTM)	77.34%	67.98%

Financial Strength

Current Ratio (MRQ)

CRM

1.07

Software Industry

Max: 3.83
Q3: 2.31
Median: 1.45
Q1: 1.03
Min: 0.24

CRM’s Current Ratio of 1.07 aligns with the median group of the Software industry, indicating that its short-term liquidity is in line with its sector peers.

JNJ

1.01

Pharmaceuticals Industry

Max: 4.49
Q3: 2.77
Median: 1.74
Q1: 1.26
Min: 0.11

JNJ’s Current Ratio of 1.01 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.

CRM vs. JNJ: A comparison of their Current Ratio (MRQ) against their respective Software and Pharmaceuticals industry benchmarks.

Debt-to-Equity Ratio (MRQ)

CRM

0.14

Software Industry

Max: 2.14
Q3: 0.90
Median: 0.29
Q1: 0.00
Min: 0.00

CRM’s Debt-to-Equity Ratio of 0.14 is typical for the Software industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

JNJ

0.65

Pharmaceuticals Industry

Max: 2.44
Q3: 1.07
Median: 0.42
Q1: 0.11
Min: 0.00

JNJ’s Debt-to-Equity Ratio of 0.65 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

CRM vs. JNJ: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Software and Pharmaceuticals industry benchmarks.

Interest Coverage Ratio (TTM)

CRM

19.86

Software Industry

Max: 67.02
Q3: 19.86
Median: 0.70
Q1: -12.50
Min: -53.00

CRM’s Interest Coverage Ratio of 19.86 is positioned comfortably within the norm for the Software industry, indicating a standard and healthy capacity to cover its interest payments.

JNJ

34.01

Pharmaceuticals Industry

Max: 103.95
Q3: 44.18
Median: 9.83
Q1: 2.82
Min: -42.71

JNJ’s Interest Coverage Ratio of 34.01 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.

CRM vs. JNJ: A comparison of their Interest Coverage Ratio (TTM) against their respective Software and Pharmaceuticals industry benchmarks.

Financial Strength at a Glance

Symbol	CRM	JNJ
Current Ratio (MRQ)	1.07	1.01
Quick Ratio (MRQ)	0.98	0.68
Debt-to-Equity Ratio (MRQ)	0.14	0.65
Interest Coverage Ratio (TTM)	19.86	34.01

Growth

Revenue Growth

CRM vs. JNJ: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

CRM vs. JNJ: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

CRM

0.66%

Software Industry

Max: 0.08%
Q3: 0.03%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

CRM’s Dividend Yield of 0.66% is exceptionally high, placing it well above the typical range for the Software industry. While this may seem attractive, an unusually high yield can sometimes be a warning sign, reflecting a falling stock price or market concerns about the dividend’s sustainability.

JNJ

2.81%

Pharmaceuticals Industry

Max: 6.98%
Q3: 3.32%
Median: 2.13%
Q1: 0.14%
Min: 0.00%

JNJ’s Dividend Yield of 2.81% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.

CRM vs. JNJ: A comparison of their Dividend Yield (TTM) against their respective Software and Pharmaceuticals industry benchmarks.

Dividend Payout Ratio (TTM)

CRM

25.00%

Software Industry

Max: 1.32%
Q3: 0.53%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

At 25.00%, CRM’s Dividend Payout Ratio is exceptionally high, exceeding the typical range for the Software industry. While this provides a significant return to shareholders, it may limit funds for reinvestment and could be difficult to sustain.

JNJ

53.34%

Pharmaceuticals Industry

Max: 165.20%
Q3: 90.59%
Median: 49.13%
Q1: 28.91%
Min: 0.00%

JNJ’s Dividend Payout Ratio of 53.34% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.

CRM vs. JNJ: A comparison of their Dividend Payout Ratio (TTM) against their respective Software and Pharmaceuticals industry benchmarks.

Dividend at a Glance

Symbol	CRM	JNJ
Dividend Yield (TTM)	0.66%	2.81%
Dividend Payout Ratio (TTM)	25.00%	53.34%

Valuation

Price-to-Earnings Ratio (TTM)

CRM

37.90

Software Industry

Max: 149.35
Q3: 100.21
Median: 47.97
Q1: 26.77
Min: 11.68

CRM’s P/E Ratio of 37.90 is within the middle range for the Software industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.

JNJ

18.99

Pharmaceuticals Industry

Max: 42.51
Q3: 26.88
Median: 19.11
Q1: 15.12
Min: 0.00

JNJ’s P/E Ratio of 18.99 is within the middle range for the Pharmaceuticals industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.

CRM vs. JNJ: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Software and Pharmaceuticals industry benchmarks.

Price-to-Sales Ratio (TTM)

CRM

6.09

Software Industry

Max: 25.24
Q3: 13.52
Median: 8.15
Q1: 4.87
Min: 0.98

CRM’s P/S Ratio of 6.09 aligns with the market consensus for the Software industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

JNJ

4.75

Pharmaceuticals Industry

Max: 7.55
Q3: 4.54
Median: 2.11
Q1: 1.52
Min: 0.00

JNJ’s P/S Ratio of 4.75 is in the upper echelon for the Pharmaceuticals industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.

CRM vs. JNJ: A comparison of their Price-to-Sales Ratio (TTM) against their respective Software and Pharmaceuticals industry benchmarks.

Price-to-Book Ratio (MRQ)

CRM

4.25

Software Industry

Max: 30.95
Q3: 14.91
Median: 7.75
Q1: 3.60
Min: 0.38

CRM’s P/B Ratio of 4.25 is within the conventional range for the Software industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.

JNJ

4.68

Pharmaceuticals Industry

Max: 9.78
Q3: 4.96
Median: 2.23
Q1: 1.46
Min: 0.60

JNJ’s P/B Ratio of 4.68 is within the conventional range for the Pharmaceuticals industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.

CRM vs. JNJ: A comparison of their Price-to-Book Ratio (MRQ) against their respective Software and Pharmaceuticals industry benchmarks.

Valuation at a Glance

Symbol	CRM	JNJ
Price-to-Earnings Ratio (TTM)	37.90	18.99
Price-to-Sales Ratio (TTM)	6.09	4.75
Price-to-Book Ratio (MRQ)	4.25	4.68
Price-to-Free Cash Flow Ratio (TTM)	18.59	23.20